Navigation Links
Replidyne's Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
Date:9/19/2007

of action that inhibits growth and targets both sporulation and toxin production, REP3123 could be a future treatment option that tackles the main challenges associated with treating CDAD: high rates of relapse and new outbreaks," stated Kenneth J. Collins, Replidyne's President & CEO. "We are excited by the potential of REP3123 and look forward to its further development."

About Clostridium difficile

C. difficile is a Gram-positive anaerobic bacterium that causes C. difficile-associated disease (CDAD). According to the Centers for Disease Control and Prevention, CDAD is on the rise worldwide, both in terms of number of cases and severity of the disease. Most cases of CDAD occur in a hospital setting due to increased use of antibiotics and other chemotherapeutics that disrupt normal intestinal flora, an ageing population, and difficulty of eradicating C. difficile spores. However, more recently, CDAD has been acquired in the community setting where several outbreaks with increased mortality have occurred. The emergence of an epidemic, hypervirulent C. difficile strain (BI/NAP1, 027) that produces high levels of toxins poses a real threat to public health and demands improved infection control as well as novel treatment options.

About Replidyne, Inc.

Replidyne is a biopharmaceutical company focused on discovering, developing, in-licensing and commercializing innovative anti-infective products. Replidyne's lead product, faropenem medoxomil, is a novel oral, community antibiotic, expected to be appropriate for use as a first-line antibiotic for treatment of respiratory and skin infections in adult and pediatric patients. Replidyne's second drug candidate, REP8839, is a topical anti-infective product candidate in development for the treatment of skin and wound infections, including methicillin-resistant S. aureus (MRSA) infections. Replidyne's investigational antibacterial agent REP3123 targets Gram-positive C. difficile bacteria and related dis
'/>"/>

SOURCE Replidyne, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 15, 2014 /PRNewswire-iReach/ -- Asthma is a chronic ... ages, but most commonly starts in childhood. It ... of the airways, leading to airflow limitation and ... contact with endogenous and exogenous irritants. Exposure to ... swelling of the airways, tightening of the respiratory ...
(Date:9/15/2014)... BRUSSELS , Sept. 15, 2014 Amgen ... today announced results from several exploratory analyses of the ... low bone mineral density (BMD). Romosozumab is an investigational ... the protein sclerostin, thereby increasing bone formation and decreasing ... Society for Bone and Mineral Research (ASBMR) 2014 Annual ...
(Date:9/15/2014)... 2014 myMatrixx has extended its contract with ... an expanded role that includes direct involvement in the ... nationally recognized physiatrist and pain management specialist, published author, ... workers, compensation, is Board Certified in physical medicine and ... Pain Medicine and subspecialty boarded by the American Board ...
Breaking Medicine Technology:Asthma Market to Reach 161.02 million Cases in 10MM by 2023 2Asthma Market to Reach 161.02 million Cases in 10MM by 2023 3Asthma Market to Reach 161.02 million Cases in 10MM by 2023 4Asthma Market to Reach 161.02 million Cases in 10MM by 2023 5New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 2New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 3New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 4New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 5New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 6New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 7New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 8New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 9New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 10New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 11New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 12New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 13New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 14New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 15myMatrixx Announces Expanded Role for Medical Director Steven P. Stanos, Jr., DO 2
(Date:9/15/2014)... 2014 College of Osteopathic Medicine of the ... the lobby of Western University of Health Sciences’ Patient Care ... Gomez about his medications, his blood pressure readings, and whether ... a lot. He’s a good man,” Gomez said. “He’s going ... patient are part of the Longitudinal Chronic Care Course (LC3), ...
(Date:9/15/2014)... The Best Hospitals Honor Roll ... seven hospitals using OnBase as their enterprise content ... were ranked at the top of the list, earning ... nearly 5,000 medical centers across the country with the ... highest in at least six of the sixteen specialties ...
(Date:9/15/2014)... New York, New York (PRWEB) September 15, 2014 ... against C.R. Bard, Inc. continue to move forward in ... Court, Southern District of West Virginia, Bernstein Liebhard LLP ... Court issued a Final Order on September 10th that ... litigation. The Order notes that none of the affected ...
(Date:9/15/2014)... (HealthDay News) -- U.S. heart experts recommend doctors use ... evaluating young people for underlying heart disease that could ... Association and the American College of Cardiology said in ... family medical history along with a physical examination can ... from birth) risks for sudden cardiac death. ...
(Date:9/15/2014)... A new, large cohort analysis from the prospective Prostate, ... that men who had moderate baldness affecting both the ... 45 were at a 40% increased risk of developing ... resulting in poorer prognosis relative to non-aggressive prostate cancer) ... There was no significant link between other patterns of ...
Breaking Medicine News(10 mins):Health News:COMP Takes the Long View of Health Care 2Health News:COMP Takes the Long View of Health Care 3Health News:COMP Takes the Long View of Health Care 4Health News:Seven of Top Ten Hospitals in the U.S. Leverage OnBase by Hyland ECM Solution 2Health News:C.R. Bard Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 2Health News:C.R. Bard Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 3Health News:Heart Docs Don't Recommend Routine ECGs for Young Athletes 2Health News:Heart Docs Don't Recommend Routine ECGs for Young Athletes 3Health News:Certain form of baldness at age 45 linked to higher risk of aggressive prostate cancer 2
... to unpasteurized milk rising in the United States, a ... Clinical Infectious Diseases examines the dangers of ... cornerstones of a healthy diet. However, if those ... health hazard because of possible contamination with pathogenic bacteria. ...
... Speed , , BOSTON, Dec. 16 John Hancock ... website ( www.jhltc.com ) to make it easier for financial professionals to access and ... , Enhancements to the site include: , , ... Faster speed of processing , Improved design and ...
... they know. Or maybe not. A new study published in Human Molecular ... genome must pay attention to ancestry when analyzing and interpreting their results. ... ... where their ancestors were from and odds are that they know. Or ...
... To Wear Pink Founder Terry,Wheatley announced on Wednesday at ... that the grassroots cowboy campaign to fight breast,cancer has ... the,efforts of regional rodeos and western across the country. ... cancer charities and go to national,breast cancer research projects. ...
... ROME, Dec. 16 The United Nations World Food Program (WFP) ... needs a fraction of what is proposed for financial rescue packages ... "We need to send a bold signal of hope ... Executive Director of the World Food Program, speaking from New Delhi ...
... 16 Donor mother Kim Morsching will,be among 26 float ... here on New Year,s Day. This year,s theme, "The ... gift of life possible for others. Kim,Morsching,s real-life star, ... a tragic accident in 2007. , South Dakota ...
Cached Medicine News:Health News:Unpasteurized milk poses health risks without benefits 2Health News:John Hancock LTC Enhances Producer Website 2Health News:John Hancock LTC Enhances Producer Website 3Health News:Genome-wide Association Studies Must Account for Ancestry 2Health News:Genome-wide Association Studies Must Account for Ancestry 3Health News:The Western Community Shows Its Heart by Wearing Pink! 2Health News:WFP Calls for Rescue Package for the World's Hungry 2Health News:WFP Calls for Rescue Package for the World's Hungry 3Health News:WFP Calls for Rescue Package for the World's Hungry 4Health News:Young Athlete's Gift of Life to be Honored on Rose Parade Float 2
... Products provide the surgeon ... products for unparalleled fluid ... of fine microsurgical instruments. ... is highly absorbent, fast ...
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Medicine Products: